COMMENT
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL

Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia

Sabina A Antoniu
Expert Opinion on Investigational Drugs 2009, 18 (6): 869-71
19426126

BACKGROUND: In asthma, anti-inflammatory therapy can usually reduce airway eosinophilic inflammation; but in certain subgroups this persists despite maximal therapy, and disease control is suboptimal. Mepolizumab is an anti IL-5. antibody that might reduce airway inflammation in such subgroups.

METHODS AND RESULTS: Evaluation of the efficacy and safety data on mepolizumab in two studies performed in patients with refractory and corticosteroid-dependent asthma with persistent sputum eosinophilia. Mepolizumab given intravenously once a month was able to reduce sputum/blood eosinophilia and asthma exacerbations and to improve quality of life.

CONCLUSIONS: Mepolizumab may be a promising anti-inflammatory therapy in asthma subgroups with heavy eosinophilic load in which conventional anti-inflammatory therapy is only partially effective.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

Remove bar
Read by QxMD icon Read
19426126
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"